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 Prostate cancer (PCa) is the most common malignancy and the second leading cause of 
cancer-related death of men in the United States. Since advanced PCa is initially dependent upon 
androgens, androgen-deprivation therapy (ADT) with LH-RH agonist and antiandrogen 
(bicalutamide or flutamide) is the first choice for advanced PCa. Unfortunately, after an initial 
response to ADT, PCa eventually does not respond to ADT and progresses into what is termed 
an androgen insensitive state against LH-RH agonist and antiandrogen. 
Multiple molecular mechanisms that could account for the development of resistance to 
ADT have been proposed that typically invoke the androgen receptor (AR) as a key mediator in 
the progression of PCa.1 Moreover, alterations of AR itself, which are either absent or at low 
frequency in the original androgen-dependent state, result in an androgen-hypersensitive 
situation where stimulation of PCa growth occurs at castrate levels of androgens. Therefore, in 
addition to its normal ligands, testosterone (T) and dihydrotestosterone (DHT), both 
androstenediol, a precursor of T, can activate the AR and stimulate the proliferation of LNCaP 
cells which have a mutated AR.2 T and the more active androgen DHT are important factors in 
PCa progression. These hormones are still present in PCa tissue after ADT. Specifically, when 
PCa patients are treated with ADT, serum T and DHT decreases to less than one-tenth of 
pretreatment levels. However, T and DHT in PCa tissue are still present at 20 to 40% of 
pretreatment values.2  
T and DHT in PCa tissue after medical or surgical castration are synthesized locally in 
the prostate from dehydroepiandrosterone (DHEA) of adrenal origin.3 The metabolism from 
DHEA to DHT in peripheral target tissues depends upon the level of expression of various 
steroidogenic enzymes in the specific cell types of these tissues. Adrenal DHEA is converted to 
T by 17β-hydroxysteroid dehydrogenase (17β-HSD) and 3β-HSD. And T is then converted to 
DHT by 5α-steroid reductase (SRD5A) in the prostate. Currently, two types of 3β-HSD, 
fifteen types of 17β-HSDs and 3 types of SRD5A have been identified and localized in various 
peripheral tissues, including the prostate, with specific expression patterns in each tissue.4 5 Fung 
et al. have observed increased expression of AKR1C3 (type 5 17β-HSD) in PCa tissue while 
Stanbrough et al. confirmed that ADT-resistant PCa and bone marrow metastases expressed 
increased levels of multiple genes responsible for androgen metabolism (HSD3B2, AKR1C3, 
SRD5A1, AKR1C2, AKR1C1 and UGT2B15).6 7 These studies provide support for the concept 
that PCa tissues can perform local biosynthesis of T and DHT resulting in activation of the AR. 
Recently, we demonstrated that T and DHT synthesized from DHEA in stromal cells activated 
AR in PCa epithelial cells in a paracrine fashion and stimulate PCa proliferation. Thus adrenal 
androgen DHEA contribute to the development of ADT resistance in PCa.8 
Therefore, alternative antiandrogen therapy (this is described in other section) is one of 
alternative strategies to extend the period when normal ADT (first-line hormonal therapy) is 
effective. Recently, second generation of antiandrogens, MDV3100 and RD162, of affinity to 
AR is 10 times more than bicalutamide were developed. These drugs not only block DHT 
binding to AR but also reduce the efficiency of its nuclear translocation. In phase I/II trial using 
MDV3100, 22 out of 30 castration resistant PCa (CRPC) had a sustained decline in PSA for at 
least 12 weeks.9 If these second generation antiandrogen are clinically available without severe 
adverse effect, these will be useful as another alternative antiandrogen therapy. 
 Since DHT is synthesized in prostate cancer tissue as described above, SRD5A inhibitor is 
also a candidate to inhibit progression after alternative antiandrogen therapy. SRD5A inhibitor, 
dutasteride repressed DHT synthesis and inhibit AR activity in LNCaP cells cocultured with 
stromal cells in vitro. Indeed, Shah reported phase II study using 3.5 mg dutasteride for CRPC. 
Of the 25 men 14 had disease progression by 2 months, 9 had stable disease, 2 had a partial 
response and none had a complete response. Now, The Therapy Assessed by Rising PSA (TARP) 
study is ongoing to investigates dutasteride in combination with bicalutamide to prevent or delay 
disease progression in patients with castrate-refractory prostate cancer (CRPC) after initial 
androgen deprivation therapy. 
Since the source of DHEA is derived from adrenal gland, new DHEA synthesis 
inhibitor abiraterone in place of ketokonazole may be effective for CRPC. Abiraterone inhibit 
CYP17 that is associated with DHEA synthesis from cholesterol in adrenal gland. A decline in 
PSA of 50% was observed in 28 (67%) of 42 phase II patients, and declines of 90% were 
observed in eight (19%) of 42 patients in CRPC. Now randomized phase III study comparing 
abiraterone plus prednisone versus prednisone plus placebo in CRPC patients who have 
previously received docetaxel is progressing.10  
In conclusion, we may obtain new hormone therapeutic drugs for the recurrence prostate 
cancer several years later.  It is necessary to evaluate it whether we should use them in a timing 
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